622867-52-1

Basic information

• Product Name: tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
• Synonyms: tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
• CAS NO: 622867-52-1
• Molecular Formula: C₁₅H₂₁NO₃
• Molecular Weight: 263.33214
• Mol File: 622867-52-1.mol

Chemical Properties

• Boiling Point: 403.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.153±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.44±0.10(Predicted)
• CAS DataBase Reference: tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate(622867-52-1)
• EPA Substance Registry System: tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate(622867-52-1)

Safety Data

• Hazardous Substances Data: 622867-52-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as an intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in HIV Treatment:
In the pharmaceutical industry, tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as a key intermediate in the preparation of phosphonate-substituted HIV protease inhibitors. These inhibitors play a crucial role in the treatment of AIDS and other viral infections by disrupting the replication process of the virus.
Used in Immunosuppressant Synthesis:
tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is also utilized in the synthesis of immunosuppressant heterocyclic compounds. These immunosuppressants are essential in treating or preventing diseases associated with EDG receptor-mediated signal transduction, which can lead to various autoimmune and inflammatory conditions.

Upstream product

• 170097-66-2 3,4-Dihydro-1H-isoquinoline-2.6-dicarboxylic acid 2-tert-butyl ester-6-methyl ester 
• 170097-67-3 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 371222-37-6 N-t-butoxycarbonyl 1,2,3,4-tetrahydroisoquinoline-6-formaldehyde 
• 893566-74-0 6-bromo-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 622867-53-2 6-bromomethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 1398414-92-0 C₃₁H₂₉F₃N₄O₄ 
• 1398414-95-3 C₃₄H₃₈N₄O₅ 
• 1398411-39-6 1-(6-{5-methyl-2-[2-(tetrahydofuran-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-ylmethoxy]phenyl}pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 
• 1398410-25-7 1-(6-{2-[2-(3-carboxypropane-1-sulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-ylmethoxy]-5-methylphenyl}pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 
• 1398410-29-1 1-{6-[5-methyl-2-(1,2,3,4-tetrahydroisoquinolin-6-ylmethoxy)phenyl]pyridin-2-yl}-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 
• 1398412-09-3 5-methyl-1-[6-[3-methyl-2-[(2-tetrahydropyran-4-yl-3,4-dihydro-1H-isoquinolin-6-yl)methoxy]phenyl]-2-pyridyl]imidazole-4-carboxylic acid 
• 1398414-91-9 ethyl 1-(6-(5-methyl-2-((1,2,3,4-tetrahydroisoquinolin-6-yl)methoxy)phenyl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1579517-52-4 C₃₁H₃₄N₄O₄ 
• 1579517-50-2 C₃₆H₄₂N₄O₆ 
• 1253660-23-9 1,1-dimethylethyl 6-(t-butyldiphenylsilyloxymethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS

The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related di

Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof

Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS

The present invention provides novel pyridyloxyacetyl tetrahydroisoquinoline compounds that inhibit NAMPT and may be useful in the treatment of cancer.

ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The inventi

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, A and B are as defined herein. The invention also r

5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND

The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: [wherein, R1 represents a group —X-Q1, X-Q1-Y-Q2 or X-Q1-Y-Q2-Z-Q3, X represents a single bond, —CH2— or the like, Q1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH2—, or the like, Q2 represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR11R12— or the like, R11 and R12 each independently represents a hydrogen atom, a halogen atom or the like, Q3 represents a phenyl group which may have substituent(s), a C3-C7 cycloalkyl group which may have substituent(s), a C3-C7 cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R2 represents a C1-C3 alkyl group or the like, and R3 represents a hydrogen atom or a methyl group].